PTC Therapeutics, Inc. Payments to Acquire Debt Securities, Available-for-sale
PTC Therapeutics, Inc. (PTCT) reported Payments to Acquire Debt Securities, Available-for-sale of $921.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-07-30
- PTC Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $466.97M, a 11.02% decline year-over-year.
- PTC Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $454.67M, a 41.06% increase year-over-year.
- PTC Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $312.26M, a 137.82% increase year-over-year.
- PTC Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $204.10M, a 10.36% increase year-over-year.
- PTC Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $1.36B, a 124.27% increase from fiscal 2024.
- PTC Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $607.98M, a 249.24% increase from fiscal 2023.
- PTC Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $174.09M, a 229.93% increase from fiscal 2022.
- PTC Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $52.76M, a 84.16% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 1 month | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $466.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $921.64M 10-Q · filed 2026-07-30 | $1.23B derived: sum of 3 quarters · filed 2026-07-30 | $1.44B derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2026-03-31 | $454.67M 10-Q · filed 2026-05-07 | $766.93M derived: sum of 2 quarters · filed 2026-05-07 | $971.04M derived: sum of 3 quarters · filed 2026-05-07 | $1.50B derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-12-31 | $312.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $516.37M derived: sum of 2 quarters · filed 2026-02-19 | $1.04B derived: sum of 3 quarters · filed 2026-07-30 | $1.36B 10-K · filed 2026-02-19 | ||
| 2025-09-30 | $204.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $728.93M derived: sum of 2 quarters · filed 2026-07-30 | $1.05B 10-Q · filed 2025-11-04 | $1.18B derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-06-30 | $524.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $847.16M 10-Q · filed 2026-07-30 | $978.47M derived: sum of 3 quarters · filed 2026-07-30 | $1.16B derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $322.33M 10-Q · filed 2026-05-07 | $453.64M derived: sum of 2 quarters · filed 2026-05-07 | $638.59M derived: sum of 3 quarters · filed 2026-05-07 | $825.95M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $131.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $316.25M derived: sum of 2 quarters · filed 2026-02-19 | $503.61M derived: sum of 3 quarters · filed 2026-02-19 | $607.98M 10-K · filed 2026-02-19 | ||
| 2024-09-30 | $184.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $372.31M derived: sum of 2 quarters · filed 2025-11-04 | $476.68M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $187.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $291.73M 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | $104.37M 10-Q · filed 2025-05-06 | |||||
| 2023-12-31 | $174.09M 10-K · filed 2026-02-19 | |||||
| 2022-12-31 | $12.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $12.34M derived: sum of 2 quarters · filed 2025-02-27 | $13.73M derived: sum of 3 quarters · filed 2025-02-27 | $52.76M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $1.39M derived: sum of 2 quarters · filed 2023-10-26 | $40.43M 10-Q · filed 2023-10-26 | $97.20M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $40.43M 10-Q · filed 2023-08-03 | $97.20M derived: sum of 3 quarters · filed 2024-02-29 | $180.65M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-03-31 | $39.03M 10-Q · filed 2023-04-27 | $95.81M derived: sum of 2 quarters · filed 2024-02-29 | $179.25M derived: sum of 3 quarters · filed 2024-02-29 | $230.20M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2021-12-31 | $56.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $140.22M derived: sum of 2 quarters · filed 2024-02-29 | $191.16M derived: sum of 3 quarters · filed 2024-02-29 | $333.15M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $83.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $134.39M derived: sum of 2 quarters · filed 2022-10-27 | $276.38M 10-Q · filed 2022-10-27 | $709.10M derived: sum of 4 quarters · filed 2023-02-21 | ||
| 2021-06-30 | $50.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $192.93M 10-Q · filed 2022-08-04 | $625.65M derived: sum of 3 quarters · filed 2023-02-21 | $1.27B derived: sum of 4 quarters · filed 2023-02-21 | ||
| 2021-03-31 | $141.99M 10-Q · filed 2022-05-03 | $574.70M derived: sum of 2 quarters · filed 2023-02-21 | $1.21B derived: sum of 3 quarters · filed 2023-02-21 | $1.28B derived: sum of 4 quarters · filed 2023-02-21 | ||
| 2020-12-31 | $432.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $1.07B derived: sum of 2 quarters · filed 2023-02-21 | $1.14B derived: sum of 3 quarters · filed 2023-02-21 | $1.44B 10-K · filed 2023-02-21 | $10.00M 10-K · filed 2021-02-25 | |
| 2020-09-30 | $639.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $708.13M derived: sum of 2 quarters · filed 2021-10-28 | $1.01B 10-Q · filed 2021-10-28 | |||
| 2020-06-30 | $68.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $367.10M 10-Q · filed 2021-07-29 | ||||
| 2020-03-31 | $298.81M 10-Q · filed 2021-05-04 | |||||
| 2020-01-31 | $10.00M 10-K · filed 2021-02-25 | |||||
| 2019-12-31 | $494.07M 10-K · filed 2022-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |